SLKDT intervention significantly inhibited obesity‐induced inflammation by decreasing the proinflammatory factors IL‐6, TNF‐α, IFN‐γ, and IL‐1β and increasing the anti‐inflammatory cytokines IL‐4 and IL‐10. The gene discussed is IL10; the disease is obesity disorder.